March 24 2010

Psychiatrists' Relationships With Pharmaceutical CompaniesPart of the Problem or Part of the Solution?

Author Affiliations

Author Affiliation: National Institute of Mental Health, Bethesda, Maryland.

JAMA. 2010;303(12):1192-1193. doi:10.1001/jama.2010.317

Psychiatrists have rarely enjoyed a surplus of public trust. During the past 3 years, public trust in psychiatry has been further undermined with accusations that several leading academic psychiatrists failed to disclose financial conflicts of interest. Sen Charles Grassley (R, Iowa), ranking member of the Finance Committee, has thus far accused 7 psychiatrists of failing to disclose income from pharmaceutical companies. As public trust in the pharmaceutical industry has plummeted, the close connection between leading psychiatrists and the pharmaceutical industry, once a sign of progress for the profession, is now cited as evidence of corrupt influence.1

First Page Preview View Large
First page PDF preview
First page PDF preview